These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24877250)

  • 1. Suboptimal management of unfractionated heparin compared with low-molecular-weight heparin in the management of pulmonary embolism.
    Khor YH; Smith R; McDonald CF
    Intern Med J; 2014 Apr; 44(4):339-44. PubMed ID: 24877250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.
    Wang C; Zhai Z; Yang Y; Cheng Z; Ying K; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Davidson BL;
    Clin Respir J; 2016 Sep; 10(5):596-605. PubMed ID: 25619125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and low molecular weight heparin in older people in a hospital with ambulatory care.
    Chan DK; Ong B; Almafragy H; Karr M; Hung AW; Liu JG
    Arch Gerontol Geriatr; 2006; 43(2):233-41. PubMed ID: 16359739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis.
    Ishi SV; Lakshmi M; Kakde ST; Sabnis KC; Jagannati M; Girish TS; Jeyaseelan L; Cherian AM
    J Assoc Physicians India; 2013 Dec; 61(12):882-6. PubMed ID: 24968543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pulmonary thromboembolism after thrombolytic treatment : randomized controlled parallel group study.
    Ucar EY; Akgun M; Araz O; Tas H; Kerget B; Meral M; Kaynar H; Saglam L
    Lung; 2015 Feb; 193(1):121-7. PubMed ID: 25351610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin.
    Prucnal CK; Jansson PS; Deadmon E; Rosovsky RP; Zheng H; Kabrhel C
    Acad Emerg Med; 2020 Feb; 27(2):117-127. PubMed ID: 31625654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute pulmonary embolism in cancer patients admitted to intensive care unit: Impact of anticoagulant treatment on 90-day mortality and risk factors, results of a multicentre retrospective study.
    Mokart D; Serre E; Bruneel F; Kouatchet A; Lemiale V; Chow-Chine L; Faucher M; Sannini A; Valade S; Bisbal M; Gonzalez F; Servan L; Darmon M; Azoulay E
    Thromb Res; 2024 May; 237():129-137. PubMed ID: 38583310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Initial Anticoagulation Among US Patients Hospitalized With Acute Pulmonary Embolism 2011-2020.
    Westafer LM; Presti T; Shieh MS; Pekow PS; Barnes GD; Kapoor A; Lindenauer PK
    Ann Emerg Med; 2024 Nov; 84(5):518-529. PubMed ID: 38888528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
    Akl EA; Labedi N; Terrenato I; Barba M; Sperati F; Sempos EV; Muti P; Cook D; Schünemann H
    Cochrane Database Syst Rev; 2011 Nov; (11):CD009447. PubMed ID: 22071865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
    Akl EA; Kahale L; Sperati F; Neumann I; Labedi N; Terrenato I; Barba M; Sempos EV; Muti P; Cook D; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD009447. PubMed ID: 24966161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Dongen CJ; van den Belt AG; Prins MH; Lensing AW
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001100. PubMed ID: 15495007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Analysis of Low-Molecular-Weight Heparin and Unfractionated Heparin in Pediatric Trauma Patients: A Comparative Analysis.
    Culbert MH; Hamidi M; Zeeshan M; Hanna K; Romero A; Joseph B; O'Keeffe T
    J Surg Res; 2020 May; 249():121-129. PubMed ID: 31931398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.